Skip to main content

Table 2 Treatment modalities of participants in RAMP-DM group and usual care group at baseline and 12 months

From: Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study

  RAMP-DM (N = 1072) Usual care (N = 1072)  
  n(%) P-valuea
Treatment Modalities at baseline
On oral glucose-lowering drugs 949 (88.5%) 941 (87.8%) 0.593
On insulin 17 (1.59%) 76 (7.1%) <0.001
On anti-hypertensive drugs 835 (77.9%) 818 (76.3%) 0.382
On lipid-lowering drugs 866 (80.8%) 880 (82.1%) 0.437
Treatment Modalities at 12 months
On oral glucose-lowering drugs 967 (90.2%) 949 (88.5%) 0.207
On insulin 63 (5.9%) 115 (10.7%) <0.001
On anti-hypertensive drugs 871 (81.3%) 852 (79.5%) 0.302
On lipid-lowering drugs 935 (87.2%) 949 (88.5%) 0.354
Enrolled in PEP 77 (7.2%) 28 (2.6%) <0.001
Receiving nurse assessment 1072 (100%) -- --
Receiving nurse intervention 766 420 (39.2%) -- --
Receiving associate consultant intervention 143 (13.3%) -- --
Receiving allied health professionals intervention 190 (17.8%) 12 (1.1%) <0.001
  1. aChi square test.
  2. PEP, patient empowerment program.